Adaptive Biotechnologies Corp

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

ADPT$29.36-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity (Continued)

(in thousands, except share amounts)

Common Stock · Additional · Accumulated Other · Accumulated · Noncontrolling · Total
	Shares	Amount	Paid-In Capital	Comprehensive Gain	Deficit	Interest	Shareholders’ Equity
Balance at December 31, 2023	145,082,271	$14	$1,452,502	$215	$(1,144,332)	$(121)	$308,278
Issuance of common stock for cash upon exercise of stock options	65,900	—	114	—	—	—	114
Vesting of restricted stock units, net	2,413,415	—	—	—	—	—	—
Share-based compensation expense	—	—	40,778	—	—	—	40,778
Other comprehensive income	—	—	—	282	—	—	282
Net loss	—	—	—	—	(125,800)	(78)	(125,878)
Balance at September 30, 2024	147,561,586	$14	$1,493,394	$497	$(1,270,132)	$(199)	$223,574
Balance at December 31, 2024	147,773,744	$14	$1,506,353	$166	$(1,303,824)	$(224)	$202,485
Issuance of common stock for cash upon exercise of stock options	1,394,132	1	8,837	—	—	—	8,838
Vesting of restricted stock units and market-based restricted stock units	3,413,166	—	—	—	—	—	—
Share-based compensation expense	—	—	38,763	—	—	—	38,763
Other comprehensive income	—	—	—	45	—	—	45
Net (loss) income	—	—	—	—	(45,920)	42	(45,878)
Balance at September 30, 2025	152,581,042	$15	$1,553,953	$211	$(1,349,744)	$(182)	$204,253

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.